When your patients need reliable, rapid COVID-19 testing, turn to the BD Veritor™ Plus System.
It offers dependable results at the point of care in a simple-to-operate portable instrument.
| PPA† | NPA* | Results in |
COVID-19 (SARS-CoV-2) | 84% (95% CI, 67%-93%) | 100% (95% CI, 98%-100%) |
15 minutes
|
COVID-19 results in 15 minutes
†positive percent agreement
‡negative percent agreement
Ordering information | Cat no. | Qty |
BD Veritor™ Plus System SARS-CoV-2 kit | 256082 | 30 tests |
BD Veritor™ Plus Analyzer | 256066 | 1 unit |
Adapts easily to your workflow by offering 2 operational modes
Displays easy-to-read digital results for COVID-19 in 15 minutes1 :
Provides clear, objective results by correcting for nonspecific binding and detecting faint lines not recognized by the unaided eye3
The BD Veritor™ Plus System provides an easy sample-collection process that can be incorporated across a variety of clinical settings.
See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.
1. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2. Package insert. 500048916 Becton, Dickinson and Company.
BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663
*EUA Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays: These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, the emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
bd.com